Antipyretic activity of fluproquazone in man. 1981

S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried

A multicentric, double-blind, randomized, parallel-group study was performed in patients with fever of diverse origin to test the tolerance and the antipyretic activity of single oral doses of 4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) (200 mg, n = 18), acetylsalicylic acid (ASA) (1000 mg, n = 22) and placebo (n = 19). Whereas with placebo mean rectal temperature remained constant, a continuous fall was recorded with both active medications over the whole 3-h study period. With fluproquazone normalization of body temperature was nearly reached. Fluproquazone was more effective than placebo (p less than 0.001) and ASA (p less than 0.1), which in turn was more active than placebo (p less than 0.0001). No specific side-effects occurred.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D001831 Body Temperature The measure of the level of heat of a human or animal. Organ Temperature,Body Temperatures,Organ Temperatures,Temperature, Body,Temperature, Organ,Temperatures, Body,Temperatures, Organ
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic

Related Publications

S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 1991, Agents and actions. Supplements,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 1981, Arzneimittel-Forschung,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 1981, Arzneimittel-Forschung,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 2016, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 1981, Arzneimittel-Forschung,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 1981, Arzneimittel-Forschung,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
May 1981, Rheumatology and rehabilitation,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
September 1977, Singapore medical journal,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
January 1990, Acta physiologica Polonica,
S Fankhauser, and W Laube, and H R Marti, and H R Schultheiss, and J Vögtlin, and B von Graffenried
May 1982, Rheumatology and rehabilitation,
Copied contents to your clipboard!